AR118788A1 - Moléculas para terapia y diagnóstico - Google Patents

Moléculas para terapia y diagnóstico

Info

Publication number
AR118788A1
AR118788A1 ARP200101170A ARP200101170A AR118788A1 AR 118788 A1 AR118788 A1 AR 118788A1 AR P200101170 A ARP200101170 A AR P200101170A AR P200101170 A ARP200101170 A AR P200101170A AR 118788 A1 AR118788 A1 AR 118788A1
Authority
AR
Argentina
Prior art keywords
disease
synuclein
molecules
lewy
dementia
Prior art date
Application number
ARP200101170A
Other languages
English (en)
Inventor
John Warner
Elpida Tsika
Original Assignee
Ac Immune Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ac Immune Sa filed Critical Ac Immune Sa
Publication of AR118788A1 publication Critical patent/AR118788A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente se refiere a moléculas que pueden emplearse para la prevención, el alivio, el tratamiento y/o el diagnóstico de enfermedades, trastornos y anormalidades asociadas con agregados de alfa-sinucleína (a-sinucleína, A-sinucleína, aSinucleína, A-sin, a-sin, aSin, a-sin), incluyendo, aunque sin limitaciones, cuerpos de Lewy y/o neuritas de Lewy, tales como enfermedad de Parkinson, atrofia sistémica múltiple, demencia de cuerpos de Lewy (LBD; demencia con cuerpos de Lewy (DLB) (demencia de cuerpos de Lewy “pura”), demencia de la enfermedad de Parkinson (PDD)) o enfermedad de cuerpos de Lewy difusos. La presente se refiere a moléculas de unión a alfa-sinucleína, en particular a anticuerpos de alfa-sinucleína o un fragmento de unión a antígeno o un derivado del mismo y a sus usos. Las presentes moléculas también se pueden usar para determinar una predisposición a dicho trastorno, enfermedad o anormalidad, para monitorear un trastorno, enfermedad o anormalidad residual, o para predecir la respuesta de un paciente que sufre de dicho trastorno, enfermedad o anormalidad al tratamiento con un determinado medicamento.
ARP200101170A 2019-04-18 2020-04-24 Moléculas para terapia y diagnóstico AR118788A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19170207 2019-04-18

Publications (1)

Publication Number Publication Date
AR118788A1 true AR118788A1 (es) 2021-11-03

Family

ID=66290208

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200101170A AR118788A1 (es) 2019-04-18 2020-04-24 Moléculas para terapia y diagnóstico

Country Status (1)

Country Link
AR (1) AR118788A1 (es)

Similar Documents

Publication Publication Date Title
BR112018068066A2 (pt) compostos bicíclicos para diagnóstico e terapia
Bordet et al. Towards the concept of disease-modifier in post-stroke or vascular cognitive impairment: a consensus report
Lim et al. Abnormal hippocampal neurogenesis in Parkinson’s disease: relevance to a new therapeutic target for depression with Parkinson’s disease
Wang et al. Inhibition of activated astrocyte ameliorates lipopolysaccharide-induced depressive-like behaviors
Pereira Dias et al. Consequences of cancer treatments on adult hippocampal neurogenesis: implications for cognitive function and depressive symptoms
Pinheiro et al. Long-lasting recognition memory impairment and alterations in brain levels of cytokines and BDNF induced by maternal deprivation: effects of valproic acid and topiramate
MX2021012608A (es) Nuevas moleculas para terapia y diagnostico.
Brown et al. Effects of chronic prednisone therapy on mood and memory
Amidfar et al. Effectiveness of memantine on depression-like behavior, memory deficits and brain mRNA levels of BDNF and TrkB in rats subjected to repeated unpredictable stress
MX2020012932A (es) Nuevos compuestos para diagnostico.
Chollet et al. Serotonin selective reuptake inhibitors (SSRIs) and stroke
CR20190468A (es) Métodos para tratar enfermedades y trastornos mediados por completo
Cusin et al. Rapid improvement of depression and psychotic symptoms in Huntington's disease: a retrospective chart review of seven patients treated with electroconvulsive therapy
Cahana-Amitay et al. Psycholinguistics of aphasia pharmacotherapy: Asking the right questions
Pain et al. Neuroprotective effects of neuropeptide Y against neurodegenerative disease
CL2023001580A1 (es) Uso de roluperidona para tratar síntomas y trastornos negativos, aumentar la neuroplasticidad y promover la neuroprotección
Jang et al. Seizure‐Induced Regulations of Amyloid‐β, STEP61, and STEP61 Substrates Involved in Hippocampal Synaptic Plasticity
Vila-Merkle et al. Sex differences in amygdalohippocampal oscillations and neuronal activation in a rodent anxiety model and in response to infralimbic deep brain stimulation
CL2019003903A1 (es) Uso de edaravona en el tratamiento oral de trastornos neurodegenerativos medidos por estrés oxidativo.
Yan et al. Transcutaneous vagus nerve stimulation: a new strategy for Alzheimer’s disease intervention through the brain-gut-microbiota axis?
Byeon The effect of computer based cognitive rehabilitation program on the improvement of generative naming in the elderly with mild dementia: preliminary study
AR118788A1 (es) Moléculas para terapia y diagnóstico
WO2022093552A3 (en) Rev-erb agonists
Chouhan et al. The ME7 prion model of neurodegeneration as a tool to understand and target neuroinflammation in Alzheimer’s disease
Liu et al. Dysfunction of the neurovascular unit in brain aging

Legal Events

Date Code Title Description
FB Suspension of granting procedure